Thad Clements, MD
Family Medicine · Charlotte, NCNPI 1982676565
Payments from drug & device makers
Across 99 payments — averaging $21.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$566
- Neurocrine Biosciences, Inc.$212
- AbbVie$195
- Novo Nordisk$173
- Boehringer Ingelheim$161
- Astellas Pharma US Inc$104
- plus $757 from 20 others
What the payments were for
- Food & beverage$2,15499%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 13 | $566 |
| Neurocrine Biosciences, Inc. | 2 | $212 |
| AbbVie(2 entities) | 13 | $195 |
| Novo Nordisk | 16 | $173 |
| Boehringer Ingelheim | 3 | $161 |
| Astellas Pharma US Inc | 6 | $104 |
| Johnson & Johnson | 4 | $97 |
| Lilly USA, LLC | 5 | $81 |
| Sanofi-aventis U.S. LLC | 4 | $68 |
| Pfizer | 4 | $55 |
| Sun Pharmaceutical Industries Inc. | 1 | $49 |
| Amarin Pharma, Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Merck | 3 | $43 |
| Avanir Pharmaceuticals, Inc. | 2 | $35 |
| Topcon Healthcare Solutions, Inc. | 1 | $31 |
| Sunovion Pharmaceuticals Inc. | 4 | $28 |
| Amgen | 2 | $27 |
| Exeltis, USA Inc. | 2 | $27 |
| GSK | 2 | $24 |
| Bayer | 1 | $22 |
| Novartis | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Eisai Inc. | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,168 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 940 | $333,878 |
| RinvoqUpadacitinib | 11 | $74,874 |
| XareltoRivaroxaban | 217 | $71,860 |
| MyrbetriqMirabegron | 165 | $63,010 |
| TivicayDolutegravir Sodium | 22 | $52,920 |
| NuplazidPimavanserin Tartrate | 11 | $37,670 |
| EntrestoSacubitril/Valsartan | 95 | $31,839 |
| AptiomEslicarbazepine Acetate | 22 | $29,475 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $28,333 |
| JanuviaSitagliptin Phosphate | 91 | $27,954 |
| XifaxanRifaximin | 17 | $26,067 |
| LinzessLinaclotide | 45 | $22,880 |
| CreonLipase/Protease/Amylase | 16 | $22,048 |
| NuedextaDextromethorphan Hbr/Quinidine | 29 | $21,828 |
| JardianceEmpagliflozin | 66 | $21,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Abrysvo, Premarin | $55 | $357,2261,002 claims |
| AbbVieRinvoq, Linzess, Creon | $195 | $119,80372 claims |
| Johnson & JohnsonXarelto | $97 | $71,860217 claims |
| Astellas Pharma US IncMyrbetriq | $104 | $63,010165 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $24 | $48,72897 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta | $161 | $45,555129 claims |
| Acadia Pharmaceuticals IncNuplazid | $14 | $37,67011 claims |
| NovartisEntresto | $20 | $31,83995 claims |
| Sunovion Pharmaceuticals Inc.Aptiom | $28 | $29,47522 claims |
| MerckJanuvia | $43 | $27,95491 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $35 | $21,82829 claims |
| AstraZenecaFarxiga | $566 | $19,18963 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Charlotte
- George RaadCharlotte$7.7M
- Steven BauerCharlotte$2.7M
- Melissa JonesCharlotte$1.8M
- Laura LuptonCharlotte$811K
- Kevin SodenCharlotte$558K
- Joseph KonenCharlotte$322K
- Thomas BarringerCharlotte$305K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Jewell CarrCharlotte$164K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.